James Flynn Joins ARCA biopharma Board of Directors
December 19 2022 - 4:05PM
ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James
Flynn has joined its Board of Directors.
“We are pleased to welcome James Flynn to our
Board,” said Robert E. Conway, Chairman of ARCA’s Board of
Directors. “We appreciate his participation and input on the
Company’s Board of Directors, including our process for evaluating
strategic options for the Company.”
Mr. Flynn is currently a Managing Member and
Portfolio Manager of Nerium Capital LLC, an investment adviser he
founded in 2021. Nerium Capital LLC is the General Partner of
Nerium Partners LP, a healthcare focused investment partnership.
Mr. Flynn also currently serves as a Board Member for Axiom Health,
a provider of software and big-data solutions to the healthcare
industry, since 2022, and has been an advisor to the company since
2020. From 2017 to 2018, Mr. Flynn worked as a therapeutics
analyst at Aptigon Capital (a Citadel Company), an investment firm.
Prior to that, from 2003 to 2017, Mr. Flynn served in various roles
at Amici Capital, LLC, an investment firm, including healthcare
portfolio manager (2008 to 2017). From 2002 to 2003, Mr. Flynn
worked in the credit research/high yield group at Putnam
Investments, an investment firm. Mr. Flynn earned a S.B. degree in
Management Science with a concentration in Finance and a minor in
Economic Science from the Massachusetts Institute of Technology
(MIT). Mr. Flynn is a Chartered Financial Analyst (CFA)
charterholder.
In June 2022, the Company entered into a
Cooperation Agreement with Cable Car Capital LLC and its affiliates
that includes, among other terms, customary standstill provisions
and the right for Cable Car to nominate an additional director
nominee at the Company’s 2022 Annual Stockholder Meeting. The
Company and Cable Car initiated a process and subsequently
identified a mutually acceptable second independent director, Mr.
Flynn, to join the Company’s Board of Directors. Mr. Flynn was
elected as Director at the 2022 annual meeting of stockholders.
About ARCA biopharmaARCA
biopharma is dedicated to developing genetically and other targeted
therapies for cardiovascular diseases through a precision medicine
approach to drug development. At present, ARCA is evaluating
options for development of its assets, including partnering and
other strategic options. For more information, please visit
www.arcabio.com.
Investor & Media
Contact:Jeff Dekker720.940.2122ir@arcabio.com
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
ARCA Biopharma (NASDAQ:ABIO)
Historical Stock Chart
From Apr 2023 to Apr 2024